News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
81 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39672)
2015 (44431)
2016 (38329)
2017 (37187)
2018 (39119)
2019 (51334)
2020 (57662)
2021 (58720)
2022 (53927)
2023 (42564)
2024 (37440)
2025 (33091)
2026 (28348)
Month
January (2935)
February (2968)
March (2710)
April (2908)
May (3627)
June (2409)
July (2088)
August (2590)
September (2381)
October (3064)
November (3189)
December (2222)
Day
2 (201)
3 (125)
4 (118)
5 (124)
6 (51)
9 (127)
10 (94)
11 (130)
12 (125)
13 (61)
16 (159)
17 (116)
18 (142)
19 (70)
20 (35)
23 (191)
24 (140)
25 (137)
26 (112)
27 (81)
30 (70)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Month
January
February
March
April
May
June
July
August
September
October
November
December
Day
2
3
4
5
6
9
10
11
12
13
16
17
18
19
20
23
24
25
26
27
30
Press Releases
BioCryst Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 Million
June 27, 2025
·
8 min read
Press Releases
FOXO TECHNOLOGIES INC. DESIGNATES NEW SERIES OF PREFERRED STOCK TO BE USED FOR ACQUISITIONS
June 27, 2025
·
4 min read
Press Releases
Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines’ Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung Cancer
June 27, 2025
·
8 min read
Press Releases
Course of Gubra A/S’ Extraordinary General Meeting Regarding Extraordinary Dividend
June 27, 2025
·
1 min read
Press Releases
LSL PHARMA GROUP SECURES $17.5 MILLION FROM DESJARDINS AND BDC
June 27, 2025
·
4 min read
Press Releases
UCB announces positive results from GEMZ Phase 3 study of fenfluramine in CDKL5 deficiency disorder
June 27, 2025
·
8 min read
Press Releases
Bone Biologics Files Patent Application for Bone Regeneration Technology
June 27, 2025
·
2 min read
Press Releases
Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right
June 27, 2025
·
8 min read
Press Releases
HCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid Tumors
June 27, 2025
·
6 min read
MASH
Altimmune Nosedives on Mixed Mid-Stage MASH Data for GLP-1/Glucagon Drug
Altimmune’s pemvidutide failed to significantly improve fibrosis in MASH patients in a Phase IIb study. The biotech crashed 53% in the aftermath of the readout.
June 27, 2025
·
2 min read
·
Tristan Manalac
Previous
5 of 9
Next
